Results 201 to 210 of about 322,252 (278)

Clinical Correlates and Predictors of Self-Harm Among Men with Substance Use Disorders

Harshpreet Kour, Gunjan Solanki, Suman Suman, Yogesh Satija   +3 more
openalex   +1 more source

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

We Must Do Better on Implementing Evidence-Based Treatments for Substance Use Disorders. [PDF]

Am J Psychiatry
Higgins ST, Erath TG.
europepmc   +1 more source

Demographic and clinical correlates of substance use disorders in first episode psychosis

Mary F. Brunette, Kim T. Mueser, Steven F. Babbin, Piper Meyer-Kalos, Robert A. Rosenheck, Christoph U. Correll, Corrine Cather, Delbert G. Robinson, Nina R. Schooler, David L. Penn, Donald Addington, Sue E. Estroff, Jennifer D. Gottlieb, Shirley M. Glynn, Patricia Marcy, James Robinson, John M. Kane   +16 more
openalex   +1 more source

Exploratory Analysis of ELP1 Expression in Whole Blood From Patients With Familial Dysautonomia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Familial dysautonomia (FD) is a hereditary neurodevelopmental disorder caused by aberrant splicing of the ELP1 gene, leading to a tissue‐specific reduction in ELP1 protein expression. Preclinical models indicate that increasing ELP1 levels can mitigate disease manifestations.
Alejandra González‐Duarte, Lucy Norcliffe‐Kaufmann, Maria Luisa Cotrina, Zenith Khan, Kaia Dalamo, Patricio Millar Vernetti, Matthew Lawless, Elisabetta Morini, Monica Salani, Marla Weetall, Jana Narasimhan, Agostino G. Rocha, Susan A. Slaugenhaupt, Horacio Kaufmann   +13 more
wiley   +1 more source

Dermatological manifestations among inpatients with substance use disorders: a comparative study of individuals with alcohol and drug use. [PDF]

BMC Psychiatry
Afacan Yıldırım E, Yıldırım YE.
europepmc   +1 more source

Understanding Rehabilitation Providers: Knowledge, Attitudes, and Practices Toward Older Adults with Substance Use Disorders [PDF]

Mike Johnson, Michelle Cathorall, Tina Newsham, Elizabeth Fugate-Whitlock   +3 more
openalex   +1 more source

Chronological and Spatial Distribution of Skeletal Muscle Fat Replacement in FHL1‐Related Myopathies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Variants in the FHL1 gene cause FHL1‐related myopathies (FHL1‐RMs), a group of neuromuscular disorders with diverse clinical presentations. This study aimed to comprehensively characterize the spatial and temporal patterns of skeletal muscle fat replacement throughout the whole body in FHL1‐RMs, to examine disease progression over ...
Rui Shimazaki, Satoru Noguchi, Hotake Takizawa, Yasushi Oya, Yuji Takahashi, Hirofumi Komaki, Hajime Arahata, Shinichiro Hayashi, Ichizo Nishino   +8 more
wiley   +1 more source

Stigma from healthcare professionals and care-limiting behaviors in individuals with substance use disorders: a mixed-methods study. [PDF]

Lancet Reg Health Eur
Luderer M, Stockreiter D, Binder A, Müller L, Burger F, Stüben N, Reif A.   +6 more
europepmc   +1 more source

Group cognitive-behavioral therapy for women with PTSD and substance use disorder

, 1996
Lisa M. Najavits, Roger D. Weiss, Bruce S. Liese   +2 more
openalex   +1 more source